免疫实践咨询委员会关于在腮腺炎疫情期间对高风险人群使用第三剂含腮腺炎病毒疫苗的建议
自2015年末以来美国腮腺炎疫情及关联病例大幅增加。免疫实践咨询委员会(ACIP)审查证据后认定,第三剂麻疹-腮腺炎-风疹(MMR)疫苗预防腮腺炎安全有效,并于2017年10月会议建议对已接种2剂、被公共卫生部门认定为疫情中高风险人群者接种第三剂含腮腺炎病毒疫苗。
要点
- ACIP建议对已接种2剂、被公共卫生部门认定为疫情中腮腺炎高风险人群者接种第三剂含腮腺炎病毒疫苗。
- 该建议旨在改善疫情环境下人群对腮腺炎及其并发症的保护。
- 该建议补充现有ACIP腮腺炎疫苗接种建议。
核心结论
- ACIP认定第三剂MMR疫苗预防腮腺炎安全有效,并建议对已接种2剂且被公共卫生部门认定为疫情中高风险人群者接种第三剂含腮腺炎病毒疫苗,以改善疫情环境下对腮腺炎及其并发症的保护。
研究设计与样本
- ACIP审查现有证据后于2017年10月会议作出建议,该建议补充现有ACIP腮腺炎疫苗接种建议。
主要发现
- 自2015年末以来,美国腮腺炎疫情及疫情关联病例数大幅增加。
关键数值与推荐
- 建议对象为既往接种过2剂、被公共卫生部门认定因疫情而属于腮腺炎感染高风险群体或人群者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A substantial increase in the number of mumps outbreaks and outbreak-associated cases has occurred in the United States since late 2015 (1,2). To address this public health problem, the Advisory Committee on Immunization Practices (ACIP) reviewed the available evidence and determined that a third dose of measles, mumps, rubella (MMR) vaccine is safe and effective at preventing mumps. During its October 2017 meeting, ACIP recommended a third dose of a mumps virus-containing vaccine* for persons previously vaccinated with 2 doses who are identified by public health authorities as being part of a group or population at increased risk for acquiring mumps because of an outbreak. The purpose of the recommendation is to improve protection of persons in outbreak settings against mumps disease and mumps-related complications. This recommendation supplements the existing ACIP recommendations for mumps vaccination (3).
引用
- Marin M, Marlow M, Moore KL, et al. Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. MMWR Morb Mortal Wkly Rep. 2018. PMID: 29324728. doi:10.15585/mmwr.mm6701a7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。